超级增强器驱动的ELOVL5通过MYC-SERBP1路径促进T-ALL的进展
Shuqi Zhang1, Wei Cheng1, Tiandan Li2
1Institute of Pediatric Research, Children's Hospital of Soochow University, No. 92 Zhongnan Street, Suzhou City 215003, Jiangsu, China; Department of Pediatrics, The First Affiliated Hospital of Wannan Medical College, Wuhu City 241001, China.
Genomics
|September 28, 2025
概括
我们发现ELOVL5,一种由超级增强剂调节的基因,是T细胞急性淋巴细胞白血病 (T-ALL) 的关键驱动因素. 沉默ELOVL5可以阻止T-ALL的进展,并改善存活率,将其确定为潜在的治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 急性淋巴细胞白血病 (ALL) 是一种常见的儿童癌症.
- T细胞ALL (T-ALL) 占儿科ALL病例的10-25%. 这种病例在儿童中占10-25%.
- 在T-ALL中识别新型瘤基因对于治疗开发至关重要.
研究的目的:
- 调查ELOVL5在T-ALL病变发生中的作用.
- 阐明ELOVL5在T-ALL中的调控机制.
- 探索ELOVL5作为T-ALL.的潜在治疗点.
主要方法:
- 在患者样本和细胞模型中对H3K27acChIP-seq分析.
- 在体外和体内功能研究涉及ELOVL5敲击.
- RNA-sequencing (RNA-seq) 用于识别下游效应者.
- 鼠标异种移植模型以评估治疗疗效.
主要成果:
- 确定ELOVL5是一种超强增强剂驱动的瘤基因,在T-ALL中表达高,与生存率差相关.
- 在试验室和体内,ELOVL5 knockdown抑制了T-ALL细胞的增殖,并诱导了亡.
- 在老鼠异种移植模型中,ELOVL5沉默降低了瘤负担和延长了生存时间.
- ELOVL5通过ELOVL5-SERBP1-MYC轴促进T-ALL的进展,激活MYC信号并上调SERBP1.
结论:
- ELOVL5是T-ALL中的关键瘤驱动因素,由超级增强剂调节.
- ELOVL5-SERBP1-MYC轴对于T-ALL进展至关重要.
- ELOVL5代表了T细胞急性淋巴细胞白血病的一个有前途的治疗标.
相关概念视频
Induced Pluripotent Stem Cells
5.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.4K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
TGF - β Signaling Pathway
10.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.5K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Eukaryotic Transcription Activators
12.5K
Transcription activators are proteins that promote the transcription of genes from DNA to RNA. In most cases, these proteins contain two separate domains ‒ a domain that binds to DNA and a domain for activating transcription; however, in some cases, a single domain is responsible for both binding and activation of transcription, as seen in the glucocorticoid receptor and MyoD.
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
12.5K


